LRRK2 and ubiquitination: Implications for Kinase inhibitor therapy

Biochemical Journal

Volumn 470, Issue 3, 2015, Pages e21-e24

  Melrose, Heather L ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

GNE1023; Kinase inhibitor; LRRK2; Parkinson's disease; Phosphorylation site; Ubiquitin

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN 14 3 3; PROTEIN SERINE THREONINE KINASE;

DOPAMINE RELEASE; HUMAN; NONHUMAN; PARKINSON DISEASE; PHOSPHORYLATION AND DEPHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; UBIQUITINATION; ANIMAL; CYTOPLASM; METABOLISM; MUTATION;

14-3-3 PROTEINS; ANIMALS; CYTOPLASM; HUMANS; MUTATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84942313644     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150785     Document Type: Review

References (50)

1. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
2. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
3. Ishihara, L., Gibson, R.A., Warren, L., Amouri, R., Lyons, K., Wielinski, C., Hunter, C., Swartz, J.E., Elango, R., Akkari, P.A. et al. (2007) Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov. Disord. 22, 55-61
4. Kachergus, J., Mata, I.F., Hulihan, M., Taylor, J.P., Lincoln, S., Aasly, J., Gibson, J.M., Ross, O.A., Lynch, T., Wiley, J. et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672-680
5. Ozelius, L.J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A.L., Klein, C., Henick, B., Hailpern, S.M. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424-425
6. Kay, D.M., Kramer, P., Higgins, D., Zabetian, C.P. and Payami, H. (2005) Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov. Disord. 20, 1077-1078
7. Liu, Z. and Lenardo, M.J. (2012) The role of LRRK2 in inflammatory bowel disease. Cell Res. 22, 1092-1094
8. Vora, P. and McGovern, D.P. (2012) LRRK2 as a negative regulator of NFAT: implications for the pathogenesis of inflammatory bowel disease. Expert Rev. Clin. Immunol. 8, 227-229
9. Liu, Z., Lee, J., Krummey, S., Lu, W., Cai, H. and Lenardo, M.J. (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 12, 1063-1070
10. Agalliu, I., San Luciano, M., Mirelman, A., Giladi, N., Waro, B., Aasly, J., Inzelberg, R., Hassin-Baer, S., Friedman, E., Ruiz-Martinez, J. et al. (2015) Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol. 72, 58-65
11. Bandmann, O. and Cookson, M.R. (2012) Parkinson disease, cancer, and LRRK2: causation or association? Neurology 78, 772-773
12. Hassin-Baer, S., Laitman, Y., Azizi, E., Molchadski, I., Galore-Haskel, G., Barak, F., Cohen, O.S. and Friedman, E. (2009) The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation: association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J. Neurol. 256, 483-487
13. Marcinek, P., Jha, A.N., Shinde, V., Sundaramoorthy, A., Rajkumar, R., Suryadevara, N.C., Neela, S.K., van Tong, H., Balachander, V., Valluri, V.L. et al. (2013) LRRK2 and RIPK2 variants in the NOD 2-mediated signaling pathway are associated with susceptibility to Mycobacterium leprae in Indian populations. PLoS One 8, e73103
14. Wang, D., Xu, L., Lv, L., Su, L.Y., Fan, Y., Zhang, D.F., Bi, R., Yu, D., Zhang, W., Li, X.A. et al. (2015) Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China. Genes Immun. 16, 112-119
15. Zhang, F.R., Huang, W., Chen, S.M., Sun, L.D., Liu, H., Li, Y., Cui, Y., Yan, X.X., Yang, H.T., Yang, R.D. et al. (2009) Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609-2618
16. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner, S. et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20, 4209-4223
17. Hinkle, K.M., Yue, M., Behrouz, B., Dachsel, J.C., Lincoln, S.J., Bowles, E.E., Beevers, J.E., Dugger, B.N., Kent, C.B., Winner, B. et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener. 7, 25
18. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, 3rd, R.J. and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U.S.A. 107, 9879-9884
19. Baptista, M.A., Dave, K.D., Frasier, M.A., Sherer, T.B., Greeley, M., Beck, M.J., Varsho, J.S., Parker, G.A., Moore, C., Churchill, M.J. et al. (2013) Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One 8, e80705
20. Ness, D., Ren, Z., Gardai, S., Sharpnack, D., Johnson, V.J., Brennan, R.J., Brigham, E.F. and Olaharski, A.J. (2013) Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. PLoS One 8, e66164
21. Fuji, R.N., Flagella, M., Baca, M., Baptista, M.A., Brodbeck, J., Chan, B.K., Fiske, B.K., Honigberg, L., Jubb, A.M., Katavolos, P. et al. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med. 7, 273ra215
22. Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., Cowell, R.M. and West, A.B. (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32, 1602-1611
23. Daher, J.P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S. and West, A.B. (2014) Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U.S.A. 111, 9289-9294
24. Boddu, R., Hull, T.D., Bolisetty, S., Hu, X., Moehle, M.S., Daher, J.P., Kamal, A.I., Joseph, R., George, J.F., Agarwal, A. et al. (2015) Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. Hum. Mol. Genet. 24, 4078-4093
25. Lobbestael, E., Deman, S., De Wit, D., Taymans, J.M. and Baekelandt, V. (2015) LRRK2 kinase inhibition reduces endogenous LRRK2 protein levels in vivo. Neurodegener. Dis. 15 Suppl. 1, 1186
26. Skibinski, G., Nakamura, K., Cookson, M.R. and Finkbeiner, S. (2014) Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J. Neurosci. 34, 418-433
27. Zhao, J., Molitor, T.P., Langston, J.W. and Nichols, R.J. (2015) LRRK2 dephosphorylation increases its ubiquitination. Biochem. J. 469, 107-120
28. Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C.E., Dominguez, S.L., Solanoy, H.O., Drummond, J., Zhang, X., Ding, X. et al. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4, 164ra161
29. Rieser, E., Cordier, S.M. and Walczak, H. (2013) Linear ubiquitination: a newly discovered regulator of cell signalling. Trends Biochem. Sci. 38, 94-102
30. Dzamko, N., Deak, M., Hentati, F., Reith, A.D., Prescott, A.R., Alessi, D.R. and Nichols, R.J. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J. 430, 405-413
31. Nichols, R.J., Dzamko, N., Morrice, N.A., Campbell, D.G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A.R. and Alessi, D.R. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393-404
32. Reynolds, A., Doggett, E.A., Riddle, S.M., Lebakken, C.S. and Nichols, R.J. (2014) LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Front. Mol. Neurosci. 7, 54
33. Lobbestael, E., Zhao, J., Rudenko, I.N., Beylina, A., Gao, F., Wetter, J., Beullens, M., Bollen, M., Cookson, M.R., Baekelandt, V. et al. (2013) Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem. J. 456, 119-128
34. Yue, M., Hinkle, K.M., Davies, P., Trushina, E., Fiesel, F.C., Christenson, T.A., Schroeder, A.S., Zhang, L., Bowles, E., Behrouz, B. et al. (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol. Dis. 78, 172-195
35. Yue, M., Davies, P., Zhang, J., Tonelli, F. and Melrose, H.L. (2015) HG-11-31-01 rescues in vivo dopamine release deficits in LRRK2 G2019S knock in mice. Neurodegener. Dis. 15 Suppl. 1, 1187
36. Liu, Z., Galemmo, Jr, R.A., Fraser, K.B., Moehle, M.S., Sen, S., Volpicelli-Daley, L.A., DeLucas, L.J., Ross, L.J., Valiyaveettil, J., Moukha-Chafiq, O. et al. (2014) Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. J. Biol. Chem. 289, 32937-32951
37. Trabzuni, D., Ryten, M., Emmett, W., Ramasamy, A., Lackner, K.J., Zeller, T., Walker, R., Smith, C., Lewis, P.A., Mamais, A. et al. (2013) Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. PLoS One 8, e70724
38. Giesert, F., Hofmann, A., Burger, A., Zerle, J., Kloos, K., Hafen, U., Ernst, L., Zhang, J., Vogt-Weisenhorn, D.M. and Wurst, W. (2013) Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS One 8, e63778
39. Fu, R.H., Liu, S.P., Huang, S.J., Chen, H.J., Chen, P.R., Lin, Y.H., Ho, Y.C., Chang, W.L., Tsai, C.H., Shyu, W.C. and Lin, S.Z. (2013) Aberrant alternative splicing events in Parkinson's disease. Cell Transplant. 22, 653-661
40. Elliott, D.A., Kim, W.S., Gorissen, S., Halliday, G.M. and Kwok, J.B. (2012) Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. Mov. Disord. 27, 1004-1011
41. Davies, P., Hinkle, K.M., Sukar, N.N., Sepulveda, B., Mesias, R., Serrano, G., Alessi, D.R., Beach, T.G., Benson, D.L., White, C.L. et al. (2013) Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem. J. 453, 101-113
42. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E.N. and Shen, J. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U.S.A. 106, 14622-14627
43. Tan, E.K. (2006) Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Ann. Acad. Med. Singapore. 35, 840-842
44. Ross, O.A., Wu, Y.R., Lee, M.C., Funayama, M., Chen, M.L., Soto, A.I., Mata, I.F., Lee-Chen, G.J., Chen, C.M., Tang, M. et al. (2008) Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64, 88-92
45. Ross, O.A., Soto-Ortolaza, A.I., Heckman, M.G., Aasly, J.O., Abahuni, N., Annesi, G., Bacon, J.A., Bardien, S., Bozi, M., Brice, A. et al. (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 10, 898-908
46. Todi, S.V. and Paulson, H.L. (2011) Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci. 34, 370-382
47. Ristic, G., Tsou, W.L. and Todi, S.V. (2014) An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes. Front. Mol. Neurosci. 7, 72
48. Lee, B.H., Lee, M.J., Park, S., Oh, D.C., Elsasser, S., Chen, P.C., Gartner, C., Dimova, N., Hanna, J., Gygi, S.P. et al. (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184
49. Ng, C.H., Mok, S.Z., Koh, C., Ouyang, X., Fivaz, M.L., Tan, E.K., Dawson, V.L., Dawson, T.M., Yu, F. and Lim, K.L. (2009) Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci. 29, 11257-11262
50. Ciechanover, A. and Kwon, Y.T. (2015) Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp. Mol. Med. 47, e147